(Q33770856)

English

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models (English)

1 reference

Europe PubMed Central

29 July 2017

1 reference

ChEBI release 2020-05-28

inflammatory breast cancer

1 reference

based on heuristic

inferred from title

Massimo Cristofanilli

7

object named as

Massimo Cristofanilli

1 reference

Europe PubMed Central

29 July 2017

author name string

Zhaomei Mu

1

1 reference

Europe PubMed Central

29 July 2017

Teresa Klinowska

2

1 reference

Europe PubMed Central

29 July 2017

Xiaoshen Dong

3

1 reference

Europe PubMed Central

29 July 2017

Emily Foster

4

1 reference

Europe PubMed Central

29 July 2017

Chris Womack

5

1 reference

Europe PubMed Central

29 July 2017

Sandra V Fernandez

6

1 reference

Europe PubMed Central

29 July 2017

publication date

30 May 2014

1 reference

Europe PubMed Central

29 July 2017

Journal of Experimental & Clinical Cancer Research

1 reference

Europe PubMed Central

29 July 2017

33

1 reference

Europe PubMed Central

29 July 2017

47

1 reference

Europe PubMed Central

29 July 2017

https://scigraph.springernature.com/pub.10.1186/1756-9966-33-47

0 references

EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Inflammatory breast cancer (IBC): clues for targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Role of epidermal growth factor receptor in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Inflammatory breast cancer: what progress have we made?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Inflammatory breast cancer: the disease, the biology, the treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Molecular targets for treatment of inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Approach to inflammatory breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Prognostic markers in triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Inflammatory breast cancer: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-33-47

21 January 2018

Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-33-47

21 January 2018

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-33-47

21 January 2018

Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24886365

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trends for Inflammatory Breast Cancer: Is Survival Improving?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24886365

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24886365

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24886365

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/24886365

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1756-9966-33-47

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33770856&oldid=1973354930"